Compare CMS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMS | INSM |
|---|---|---|
| Founded | 1987 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 22.4B |
| IPO Year | 1997 | 2000 |
| Metric | CMS | INSM |
|---|---|---|
| Price | $67.52 | $95.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | $75.83 | ★ $197.00 |
| AVG Volume (30 Days) | ★ 3.9M | 2.6M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | ★ 6.01 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $8,539,000,000.00 | N/A |
| Revenue This Year | $4.97 | $196.85 |
| Revenue Next Year | $4.71 | $61.71 |
| P/E Ratio | $46.90 | ★ N/A |
| Revenue Growth | ★ 13.63 | N/A |
| 52 Week Low | $62.29 | $90.39 |
| 52 Week High | $80.36 | $212.75 |
| Indicator | CMS | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 29.46 |
| Support Level | $67.19 | $90.39 |
| Resistance Level | $69.36 | $119.54 |
| Average True Range (ATR) | 1.08 | 3.84 |
| MACD | 0.63 | -0.82 |
| Stochastic Oscillator | 77.64 | 8.96 |
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.